1.
Critical care clinics
; 2022.
Article
in English
| EuropePMC | ID: covidwho-1678718
ABSTRACT
Synopsis: SARS-CoV-2 infection leads to dysregulation of immune pathways. Therapies focusing on suppressing cytokine activity have some success. Current evidence supports the use of dexamethasone in hospitalized patients requiring oxygen to decrease mortality. IL-6 inhibitors like tocilizumab and sarilumab are also beneficial in hypoxemic patients, if used early. JAK inhibition in combination with glucocorticoids is emerging as a potential therapeutic option for patients with moderate to severe symptoms. Data on the role of anakinra, hyperimmune immunoglobulin/convalescent plasma, or plasma purification is limited.